Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Maillet

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
European Urology Oncology|November 3, 2019
Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer PatientsDenis Maillet, Nathalie Allioli, Julien Peron, et al.
Cancer Medicine|August 12, 2021
Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancerCedric Pobel, Edouard Auclin, Diego Teyssonneau, et al.
Gynecologic Oncology|October 26, 2013
Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO networkDenis Maillet, Thibaut Goulvent, Ruth Rimokh, et al.
The French Journal of Urology|June 1, 2024
Multidisciplinary real-world management of metastatic castration-sensitive prostate cancer: A French national study (PROFILE study)Carole Helissey, Denis Maillet, Bérengère Narciso, et al.
Bulletin Du Cancer|September 5, 2024
[Metastatic castration-resistant prostate cancer and PARP inhibitors: From tumor genomics to new therapeutic combinations]Stéphane Oudard, Marc-Olivier Timsit, Denis Maillet, et al.
Histopathology|June 3, 2015
DICER1 and FOXL2 mutations in ovarian sex cord-stromal tumours: a GINECO Group studyThibault Goulvent, Isabelle Ray-Coquard, Stéphane Borel, et al.
Clinical Genitourinary Cancer|December 5, 2025
Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA StudyThibaut Reverdy, Floriane Izarn, Benoit Allignet, et al.
The French Journal of Urology|October 10, 2025
Chemotherapy use in triplet approach for metastatic hormone-sensitive prostate cancer: French practice survey and expert opinionDelphine Borchiellini, Gwenaelle Gravis, Emmanuel Gross, et al.
Nature Reviews. Urology|May 17, 2018
Systemic treatments for high-risk localized prostate cancerGéraldine Pignot, Denis Maillet, Emmanuel Gross, et al.
Cancers|June 2, 2021
Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival OutcomesCharline Lafayolle de la Bruyère, Pierre-Jean Souquet, Stéphane Dalle, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
European Urology Oncology|November 3, 2019
Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer PatientsDenis Maillet, Nathalie Allioli, Julien Peron, et al.
Cancer Medicine|August 12, 2021
Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancerCedric Pobel, Edouard Auclin, Diego Teyssonneau, et al.
Gynecologic Oncology|October 26, 2013
Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO networkDenis Maillet, Thibaut Goulvent, Ruth Rimokh, et al.
The French Journal of Urology|June 1, 2024
Multidisciplinary real-world management of metastatic castration-sensitive prostate cancer: A French national study (PROFILE study)Carole Helissey, Denis Maillet, Bérengère Narciso, et al.
Bulletin Du Cancer|September 5, 2024
[Metastatic castration-resistant prostate cancer and PARP inhibitors: From tumor genomics to new therapeutic combinations]Stéphane Oudard, Marc-Olivier Timsit, Denis Maillet, et al.
Histopathology|June 3, 2015
DICER1 and FOXL2 mutations in ovarian sex cord-stromal tumours: a GINECO Group studyThibault Goulvent, Isabelle Ray-Coquard, Stéphane Borel, et al.
Clinical Genitourinary Cancer|December 5, 2025
Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA StudyThibaut Reverdy, Floriane Izarn, Benoit Allignet, et al.
The French Journal of Urology|October 10, 2025
Chemotherapy use in triplet approach for metastatic hormone-sensitive prostate cancer: French practice survey and expert opinionDelphine Borchiellini, Gwenaelle Gravis, Emmanuel Gross, et al.
Nature Reviews. Urology|May 17, 2018
Systemic treatments for high-risk localized prostate cancerGéraldine Pignot, Denis Maillet, Emmanuel Gross, et al.
Cancers|June 2, 2021
Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival OutcomesCharline Lafayolle de la Bruyère, Pierre-Jean Souquet, Stéphane Dalle, et al.
Pageof 7